ReviewF1000prime reports2014
Management of hemolytic uremic syndrome.
Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Acquired platelet disorders.Frontiers in medicine · 2025Review
- Shiga-Toxin-Producing Strains ofMicroorganisms · 2023Article
- Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome.Frontiers in immunology · 2023Article
- Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.Clinical case reports · 2022Article
- O antigen restricts lysogenization of non-O157 Escherichia coli strains by Stx-converting bacteriophage phi24B.Scientific reports · 2021Article
- Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.PloS one · 2021Article
- Shiga toxin-producingJournal of medical microbiology · 2020Article
- Intimate Attachment ofMicroorganisms · 2020Article
- Atypical Haemolytic Uraemic Syndrome Associated withCase reports in nephrology · 2018Article
- Hemolytic uremic syndrome in adults: A case report.World journal of critical care medicine · 2017Article
- Infection-related hemolysis and susceptibility to Gram-negative bacterial co-infection.Frontiers in microbiology · 2015Review
- Hemolytic Uremic syndrome associated with pregnancy: Outcome from acute Kidney Injury.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemolytic uremic syndrome (HUS) is a disease characterized by hemolysis, thrombocytopenia, and acute kidney injury, although other organs may be involved. Most cases are due to infection with Shiga toxin-producing Escherichia coli (STEC). Early identification and initiation of best supportive care, with microbiological input to identify the pathogen, result in a favorable outcome in most patients. The remaining 10% of HUS cases are classed together as atypical HUS and have a diverse etiology. The majority are due to inherited or acquired abnormalities that lead to a failure to control complement activation. Atypical HUS occurring in other situations (for example, related to pregnancy or kidney transplantation) may also involve excessive complement activation. Plasma therapies can reverse defective complement control, and it is now possible to specifically target complement activation. This has led to improved outcomes in patients with atypical forms of HUS. We will review our current understanding of the pathogenesis of HUS and how this has led to advances in patient care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.